The I-MAT trial is a randomised, placebo-controlled, phase II trial of adjuvant Avelumab in
patients with stage I-III Merkel cell carcinoma aiming to explore the efficacy of avelumab as
The I-MAT trial is a phase II, prospective, randomised, placebo-controlled,
multi-institutional trial for patients with stage I-III Merkel cell carcinoma (MCC).
Participants on the trial will receive either avelumab or placebo for 6 months. The primary
aim of the I-MAT trial is to develop an effective, well-tolerated adjuvant immunotherapy
regimen for patients with stage I-III MCC, post a range of definitive loco-regional treatment
Merkel Cell Carcinoma, Merkel Cell Carcinoma, Stage I, Merkel Cell Carcinoma, Stage II, Merkel Cell Carcinoma, Stage III, Neuroendocrine Tumors, Carcinoma Neuroendocrine Skin
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.